Gilead Sciences, Inc. (GILD)
144.74
-2.76
(-1.87%)
USD |
NASDAQ |
Oct 02, 16:00
144.92
+0.18
(+0.12%)
After-Hours: 20:00
Gilead Sciences Enterprise Value : 200.90B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 200.90B |
| October 01, 2026 | 204.33B |
| September 30, 2026 | 206.25B |
| September 29, 2026 | 209.02B |
| September 28, 2026 | 210.17B |
| September 25, 2026 | 208.58B |
| September 24, 2026 | 207.05B |
| September 23, 2026 | 209.13B |
| September 22, 2026 | 210.74B |
| September 21, 2026 | 208.12B |
| September 18, 2026 | 207.57B |
| September 17, 2026 | 208.53B |
| September 16, 2026 | 204.55B |
| September 15, 2026 | 202.84B |
| September 14, 2026 | 202.97B |
| September 11, 2026 | 199.64B |
| September 10, 2026 | 200.99B |
| September 09, 2026 | 202.03B |
| September 08, 2026 | 203.26B |
| September 04, 2026 | 208.66B |
| September 03, 2026 | 208.94B |
| September 02, 2026 | 206.95B |
| September 01, 2026 | 207.33B |
| August 31, 2026 | 202.89B |
| August 28, 2026 | 202.07B |
| Date | Value |
|---|---|
| August 27, 2026 | 206.02B |
| August 26, 2026 | 205.06B |
| August 25, 2026 | 205.90B |
| August 24, 2026 | 203.38B |
| August 21, 2026 | 202.61B |
| August 20, 2026 | 199.29B |
| August 19, 2026 | 204.45B |
| August 18, 2026 | 199.29B |
| August 17, 2026 | 193.68B |
| August 14, 2026 | 192.98B |
| August 13, 2026 | 192.71B |
| August 12, 2026 | 189.89B |
| August 11, 2026 | 189.77B |
| August 10, 2026 | 186.41B |
| August 07, 2026 | 186.59B |
| August 06, 2026 | 183.68B |
| August 05, 2026 | 184.79B |
| August 04, 2026 | 189.13B |
| August 03, 2026 | 184.04B |
| July 31, 2026 | 182.87B |
| July 30, 2026 | 184.20B |
| July 29, 2026 | 186.00B |
| July 28, 2026 | 187.97B |
| July 27, 2026 | 183.26B |
| July 24, 2026 | 181.75B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 528.72B |
| Regeneron Pharmaceuticals, Inc. | 70.72B |
| Vertex Pharmaceuticals, Inc. | 121.99B |
| Amgen, Inc. | 261.20B |
| Biogen, Inc. | 39.55B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.50B |
| Revenue (Quarterly) | 7.821B |
| Total Expenses (Quarterly) | 18.32B |
| EPS Diluted (Quarterly) | -8.444 |
| Gross Profit Margin (Quarterly) | 79.81% |
| Profit Margin (Quarterly) | -134.2% |
| Earnings Yield | -1.84% |
| Operating Earnings Yield | 6.59% |
| Normalized Earnings Yield | 3.283 |